Rosiptor - Aquinox Pharmaceuticals

Drug Profile

Rosiptor - Aquinox Pharmaceuticals

Alternative Names: AQX 1125; Rosiptor acetate

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aquinox Pharmaceuticals
  • Class Androstanes; Anti-inflammatories; Immunotherapies; Indenes; Small molecules
  • Mechanism of Action Inositol-1,4,5-trisphosphate 5-phosphatase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Interstitial cystitis
  • Phase II Allergic asthma; Prostatitis
  • Discontinued Atopic dermatitis; Chronic obstructive pulmonary disease; Haematological disorders; Hypersensitivity; Immunological disorders; Inflammation; Irritable bowel syndrome; Pulmonary fibrosis

Most Recent Events

  • 27 Jun 2018 The phase III LEADERSHIP 301 trial fails to meet its primary endpont of bladder pain score
  • 11 Jun 2018 Phase-II clinical trials in Prostatitis in USA and Canada (PO)
  • 09 May 2018 Rosiptor licensed to Astellas Pharma in Japan, and additional countries in the Asia-Pacific region, including South Korea, Australia, Taiwan, Indonesia, and Malaysia, but excluding China and India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top